Therrien J, Webb G D, Gatzoulis M A
The Toronto Congenital Cardiac Centre for Adults, The Toronto Hospital, University of Toronto, 200 Elizabeth Street, 12 EN 213, Toronto, Ontario M5G 2C4, Canada.
Heart. 1999 Aug;82(2):241-3. doi: 10.1136/hrt.82.2.241.
Protein losing enteropathy (PLE), defined as severe loss of serum protein into the intestine, occurs in 4-13% of patients after the Fontan procedure and carries a dismal prognosis with a five year survival between 46% and 59%. Chronically raised systemic venous pressure is thought to be responsible for the development of PLE in these patients, with perhaps superimposed immunological or inflammatory factors. The success rate of contemporary medical, transcatheter, and surgical treatments attempting to reduce systemic venous pressure ranges from 19% to 40%. Prednisone treatment for PLE has been tried, with variable success rates reported in children. The effect of prednisone in adult patients with PLE after the Fontan procedure is largely unknown. Two cases of PLE in adults (a 39 year old woman and a 25 year old man) after modified Fontan procedure who responded dramatically to oral prednisone treatment are reported, suggesting that a trial of this "non-invasive" treatment should be considered as long term palliation or bridge to cardiac transplantation.
蛋白丢失性肠病(PLE)定义为血清蛋白严重丢失至肠道,在Fontan手术患者中发生率为4% - 13%,预后不佳,五年生存率在46%至59%之间。长期升高的体循环静脉压被认为是这些患者发生PLE的原因,可能还伴有免疫或炎症因素叠加。当代试图降低体循环静脉压的药物、经导管和手术治疗的成功率在19%至40%之间。已尝试用泼尼松治疗PLE,儿童的成功率报道不一。泼尼松对Fontan手术后成年PLE患者的疗效很大程度上未知。本文报道了两例成年患者(一名39岁女性和一名25岁男性)在改良Fontan手术后发生PLE,口服泼尼松治疗反应显著,提示这种“非侵入性”治疗试验应被视为长期姑息治疗或心脏移植的桥梁。